Regenxbio hits Duchenne gene therapy milestone, eyes 2027 FDA approval

Regenxbio said Thursday that its Duchenne muscular dystrophy gene therapy met the bar in a pivotal study, and it’s aiming for FDA approval in 2027. The biotech hopes to be the second company to commercialize ...